Erenumab
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Erenumab: From Migraine Prevention to Migraine with Brainstem Aura
One-Sentence Summary
Erenumab is a CGRP-receptor monoclonal antibody already used for migraine prevention (episodic and chronic, with or without aura). The TxGNN model predicts it may also be effective for Migraine with Brainstem Aura, a distinct ICHD-3 subtype, with 0 clinical trials and 20 publications currently available, most of which are indirect (mechanistic, safety, or general-aura subgroup) rather than trials conducted specifically in this subtype.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Migraine prevention (episodic/chronic, with or without aura)* |
| Predicted New Indication | Migraine with Brainstem Aura |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L4 |
| Finland Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
*No formal Fimea license text is on file (0 authorizations); this reflects erenumab's internationally known approved use, cited in the repurposing rationale rather than a Finnish product label.
Why is This Prediction Reasonable?
Structured mechanism-of-action data is not available for this drug in the evidence pack. Based on the repurposing rationale, erenumab is a CGRP (calcitonin gene-related peptide) receptor monoclonal antibody, already established for migraine prevention. CGRP release in the trigeminovascular system is a well-supported driver of migraine pain, which is the pharmacological basis for erenumab's approved use.
Migraine with brainstem aura (formerly "basilar-type migraine," ICHD-3 code 1.2.2) is a specific subtype whose aura symptoms are thought to originate from brainstem dysfunction, and it is not established that this shares the same trigeminovascular mechanism as typical migraine. Extending erenumab's effect to this subtype is biologically plausible but mechanistically unconfirmed.
Notably, this subtype is commonly an exclusion criterion in pivotal CGRP monoclonal antibody trials, due to a theoretical concern about cerebral vasoconstriction risk in a population whose aura already implicates brainstem/vascular involvement. This is why the current evidence base consists of general-aura subgroup analyses and mechanistic/safety studies rather than trials enrolling this subtype directly — a real, not merely a reporting, gap.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30360965 | 2018 | RCT (Phase 3b) | Lancet | Randomized, double-blind, placebo-controlled trial of erenumab in episodic migraine after 2–4 prior preventives failed |
| 34928306 | 2022 | RCT (post-hoc analysis) | JAMA Neurology | Secondary analysis of RCTs assessing erenumab safety/efficacy in migraine with vs. without aura |
| 37012858 | 2023 | Systematic Review | Int Immunopharmacol | Systematic review of erenumab efficacy in episodic/chronic migraine prophylaxis |
| 30725283 | 2019 | Review | Handb Exp Pharmacol | Review of CGRP's role in migraine pathophysiology, underpinning erenumab's mechanism |
| 41888647 | 2026 | Cohort (REFORM) | J Headache Pain | Longitudinal changes in migraine aura frequency during/after erenumab treatment |
| 36942409 | 2023 | Cohort (pooled trial data) | Headache | Post-hoc cardiovascular risk analysis of erenumab in patients with vs. without aura |
| 40275185 | 2025 | Cohort (biomarker, REFORM) | J Headache Pain | Plasma suPAR (inflammation biomarker, elevated in aura) associated with erenumab response |
| 35151970 | 2022 | Cohort (real-world) | Clin Neurol Neurosurg | Real-world effectiveness/safety of erenumab in treatment-resistant chronic migraine |
| 35538414 | 2022 | Cohort (real-world) | J Headache Pain | 12-month real-world safety/tolerability and adverse event predictors for erenumab |
| 32867533 | 2021 | Mechanistic/Safety | Cephalalgia | Erenumab does not alter cerebral hemodynamics or endothelial function in migraine without aura |
Finland Market Information
Erenumab is not currently marketed in Finland — no marketing authorizations are on file (0 licenses).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to general-aura subgroup data, mechanistic/safety studies, and cohort data rather than trials enrolling migraine-with-brainstem-aura patients directly — this subtype is typically excluded from pivotal CGRP antibody trials over theoretical cerebrovascular risk, and the evidence level is only L4. The drug is also not currently marketed in Finland, and TFDA/Fimea label warnings and contraindications are a blocking data gap (DG001).
To proceed, the following is needed:
- TFDA/Fimea package insert (warnings, contraindications) — currently a blocking data gap
- Structured mechanism-of-action documentation from DrugBank
- Dedicated safety/efficacy data in confirmed migraine-with-brainstem-aura patients, given their theoretical cerebrovascular risk and routine exclusion from erenumab pivotal trials
- Clarification of Fimea regulatory pathway status, since the drug currently has zero Finnish authorizations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.